Skip to main content

Table 1 Patient characteristics

From: 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

 

All Patients

(n = 386)

Colorectal cancer

(n = 161)

Lung cancer

(n = 140)

Ovarian cancer

(n = 45)

Breast cancer

(n = 40)

Age,n (%) 65 years

178 (46.1)

66 (41.0)

92 (65.7)

9 (20.0)

11 (27.5)

    <  65 years

208 (53.9)

95 (59.0)

48 (34.3)

36 (80.0)

29 (72.5)

Median (range)

64 (26–84)

62 (30–79)

68 (39–84)

57 (26–76)

54.5 (37–73)

Sex (%) Female

185 (47.9)

71 (44.1)

29 (20.7)

45 (100.0)

40 (100.0)

Motion sickness (%) Yes

59 (15.3)

22 (13.7)

12 (8.6)

13 (28.9)

12 (30.0)

Drinking habit (%) Yes

203 (52.6)

79 (49.1)

83 (59.3)

23 (51.1)

18 (45.0)

Smoking habit (%) Yes

150 (38.9)

56 (34.8)

88 (62.9)

2 (4.4)

4 (10.0)

Pregnancy associated vomiting (%) Yes

95 (51.4)

34 (47.9)

20 (69.0)

20 (44.4)

21 (52.5)

Palonosetoron (%)

153 (39.6)

132 (82.0)

9 (6.4)

1 (2.2)

11 (27.5)

Regimen

     

 CBDCA (AUC5) + ETP

34 (8.8)

34 (24.3)

 CBDCA+PTX

103 (26.7)

58 (41.4)

45 (100.0)

 CBDCA (AUC5)

20

2

18

 CBDCA (AUC6)

83

56

27

 CBDCA+PEM

48 (12.4)

48 (34.3)

 

 CBDCA (AUC5)

11

11

 CBDCA (AUC6)

37

37

 DTX + CPA

40 (10.4)

40 (100.0)

 FOLFOX

79 (20.5)

79 (49.1)

 FOLFIRI

4 (1.0)

4 (2.5)

 CAPOX

78 (20.2)

78 (48.4)

  1. CBDCA Carboplatin, ETP Etoposide, PTX Paclitaxel, PEM Pemetrexed, CPA Cyclophosphamide, DTX Docetaxel, FOLFOX oxaliplatin with fluorouracil and folinic acid, FOLFIRI Irinotecan with fluorouracil and folinic acid, CAPOX Capecitabine plus oxaliplatin therapy